Business Information
The group's principal activity is to produce, market, promote and sell pharmaceutical drugs. The group is primarily into organizational activities, research and development activities and raising capital. The group operates under the trademark reticulose(R) that is currently known as avr118. This drug is used for the treatment of diseases such as cachexia, or body wasting, in patients with acquired immune deficiency syndrome (aids), and cancer; human immunodeficiency virus, or HIV, including aids as a combination therapy; human papilloma virus, or hpv, which causes genital warts and may lead to cervical cancer and rheumatoid arthritis. The group entered into distribution agreements with four separate entities granting rights to distribute reticulose in the countries of Canada, China, Japan, Hong Kong, macao, Taiwan, Mexico, Argentina, Bolivia, paraguay, uruguay, Brazil and Chile.
|
|
Name |
Title
|
Email
|
| Eli Wilner | Chmn. | N/A | | Angelo Botter | Dir. | N/A | | Nancy Van Sant | Dir. | N/A | | Roy Walzer | Dir. | N/A | | Stephen Elliston | Dir., CEO, Pres. | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | N/A | (3,847) | | 2005 | N/A | (5,200) | | 2004 | N/A | (6,213)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
